Effects of Pioglitazone and Irbesartan on Endothelial Dysfunction on Experimentally Streptozotocin-Induced Diabetic Nephropathy in Rats

Table 1: Effects of irbesartan (30mg/kg), pioglitazone (30mg/kg), and combination of irbesartan and pioglitazone in high dose and low dose on fasting blood glucose level (FBG) and 24-hour urinary albumin excretion (UAE), serum urea, and creatinine (mg/dl) in diabetic rats.


Parameters Groups	FBG (mg/dl) Mean ± SE	Urine albumin (mg/24 h) Mean ± SE	Serum urea(mg/dl) Mean ± SE	Serum creatinine(mg/dl) Mean ± SE

Control	88 ± 2.9	3.89 ± 2.3	36.4 ± 2.8	0.9 ± 0.06
DM group	200 ± 20.1 ^a	14.5 ± 1.1 ^a	145 ± 4.6 ^a	3.7 ± 0.17 ^a
Irbesartan-treated	190 ± 18.4 ^a	8.7.4 ± 0.45 ^{a b}	48.2 ± 3.1 ^b	2.1 ± 0.13 ^b
Pioglitazone-treated	112 ± 5.2 ^{b c}	7.2 ± 0.53 ^b	45.4 ± 2.9 ^b	2.3 ± 0.11 ^b
IRB+PIO high dose treated	105 ± 3.9	5.0 ± 0.4 ^{b c d}	42.1 ± 3.9 ^{b c d}	1.7 ± 0.1 ^{b c d}
IRB+PIO low dose treated	115 ± 4.1 ^{a b}	5.6 ± 0.45 ^{b c d}	39.1 ± 4.2 ^{b c d}	1.6 ± 0.1 ^{b c d}

^aSignificant difference from control group.
^bSignificant difference from diabetic group.
^cSignificant difference from irbesartan group.
^dSignificant difference from pioglitazone group.